<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04121520</url>
  </required_header>
  <id_info>
    <org_study_id>CHESS1904</org_study_id>
    <nct_id>NCT04121520</nct_id>
  </id_info>
  <brief_title>Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey</brief_title>
  <official_title>Perioperative Care of Hepatic Venous Pressure Gradient (HVPG) Measurement (CHESS1904): An International Multicenter Survey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepatopancreatobiliary Surgery Institute of Gansu Province</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xingtai People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiba University Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitas Indonesia, Cipto Mangunkusumo National General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>S. Orsola-Malpighi Hospital, University of Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidade Federal de Pernambuco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hepatopancreatobiliary Surgery Institute of Gansu Province</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic venous pressure gradient (HVPG) is an invasive test and requires technical skills of
      the operator and specialized instruments. HVPG measurement and anesthesia can cause stress
      responses in the body, which in turn lead to inflammatory response and immune function
      suppression. Thus, the perioperative care for patients undergoing HVPG measurement is
      crucial. This research trial studies comprehensive patient and medical worker questionnaires
      in predicting complications in patients with cirrhosis undergoing HVPG measurement.
      Comprehensive patient and medical worker questionnaires may help identify complications, such
      as the need for assistance in taking medication, decreased mobility and released tension that
      may improve outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Portal hypertension is an important factor affecting the clinical outcomes of cirrhosis
      patients, and its severity determines the occurrence of development of cirrhosis
      complications, such as rupture and bleeding of gastroesophageal varices, ascites, and
      hepatorenal syndrome. The direct measurement of portal pressure is an extremely invasive and
      high-risk procedure. In addition, changes in intra-abdominal pressure will affect the portal
      pressure, which leads to unreliable results. The hepatic venous pressure gradient (HVPG) is
      the difference between wedged hepatic venous pressure and free hepatic venous pressure and
      reflects the pressure difference between the hepatic portal vein and the intra-abdominal
      veins. In recent years, the status of HVPG in clinical application of cirrhotic portal
      hypertension has gradually improved. In 2016, the American Association for the Study of Liver
      Diseases (AASLD) issued a consensus on risk stratification, diagnosis, and management of
      portal hypertensive bleeding in cirrhosis and re-emphasized the value of HVPG in assessing
      the cirrhosis staging, occurrence of complications and treatment goals. However, HVPG is an
      invasive test and requires technical skills of the operator and specialized instruments. HVPG
      measurement and anesthesia can cause stress responses in the body, which in turn lead to
      inflammatory response and immune function suppression. Thus, the perioperative care for
      patients undergoing HVPG measurement is crucial. This research trial studies comprehensive
      patient and medical worker questionnaires in predicting complications in patients with
      cirrhosis undergoing HVPG measurement. Comprehensive patient and medical worker
      questionnaires may help identify complications, such as the need for assistance in taking
      medication, decreased mobility and released tension that may improve outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative satisfaction</measure>
    <time_frame>1 day</time_frame>
    <description>After the procedure of HVPG (within the same day), participants will be asked to complete a pain scale which was experienced during and after the HVPG procedure. The pain scale ranges from 0 to 10 with 0 representing 'not at all' and 10 representing 'excessively'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-operative perception</measure>
    <time_frame>1 day</time_frame>
    <description>At time of consent and within the same day of HVPG procedure, participants will be asked to complete a pain scale which was felt to be experienced during the HVPG procedure. The pain scale ranges from 0 to 10 with 0 representing 'not at all' and 10 representing 'excessively'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of intra-operative complications</measure>
    <time_frame>1 day</time_frame>
    <description>Number of complications (e.g. vasovagal reflex, arrhymia, inadvertent arterial puncture, hypersensitivity to contrast agents, pneumothorax) happened during the HVPG procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of post-operative complications</measure>
    <time_frame>1 day</time_frame>
    <description>Number of complications (e.g. bleeding at the puncture point, contrast-induced nephropathy, infection, jugular vein thrombosis) happened after the HVPG procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methods selection of HVPG measurement</measure>
    <time_frame>1 day</time_frame>
    <description>Including the selection of routes for insertion of catheter, hepatic vein used for the assessment and the angiographic catheter used during the HVPG procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The result of HVPG measurement</measure>
    <time_frame>1 day</time_frame>
    <description>The mean value of HVPG measurements.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Portal Hypertension</condition>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <description>At time of consent and within the same day of HVPG measurement, participants will be asked to complete a pre-operative assessment. Relevant statistics will be recorded during the HVPG procedure. Post-operative complication will also be collected and the satisfaction survey will be conducted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Comprehensive perioperative assessment
Questionnaire administration</description>
    <arm_group_label>Observational</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with cirrhosis who were scheduled to undergo HVPG measurement
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eligible participants must meet the following criteria:

          1. aged between 18-75 years, no restriction on gender;

          2. clinically and/or pathologically diagnosed sinusoidal cirrhosis;

          3. with written informed consent

          4. scheduled to undergo HVPG measurement according to the following indications: 1)
             assessment of the efficacy of primary and secondary prophylactic drugs for
             gastroesophageal variceal bleeding; 2) predicting the risk of gastroesophageal
             variceal bleeding and guiding the selection of the treatment regimens; 3) predicting
             of risk, progression, and clinical outcomes of decompensation events in cirrhosis; 4)
             evaluation of the efficacy of new drugs; 5) evaluation of the accuracy of new
             non-invasive techniques; diagnosis and differential diagnosis of types of portal
             hypertension.

        Exclusion Criteria:

        Those cases that meet any of the following criteria should be excluded:

          1. contradictions for HVPG measurement;

          2. pregnant or lactating woman;

          3. severe coagulopathy (international normalized ratio&gt;5);

          4. severe heart, lung, or kidney disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaolong Qi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>LanZhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Necati Örmeci, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaolong Qi, M.D.</last_name>
    <phone>+86-18588602600</phone>
    <email>qixiaolong@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xinwen Yan, M.D.</last_name>
    <phone>+86-18565120926</phone>
    <email>812895688@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidade Federal de Pernambuco</name>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Ximenes, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Rafael Ximenes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huaping Wei, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Lei Li, M.D.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Huaping Wei</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lei Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xingtai People's Hospital</name>
      <address>
        <city>Xingtai</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changzeng Zuo, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Bo Zhang, M.D.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Changzeng Zuo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bo Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital affiliated to Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunqing Zhang, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Guangchuan Wang, M.D.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Chunqing Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guangchuan Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junhui Sun, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Tanyang Zhou, M.D.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Junhui Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitas Indonesia, Cipto Mangunkusumo National General Hospital</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cosmas Rinaldi A. Lesmana, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Cosmas Rinaldi A. Lesmana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S. Orsola-Malpighi Hospital, University of Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Golfieri, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Rita Golfieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chiba University Graduate School of Medicine</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hitoshi Maruyama, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Hitoshi Maruyama</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo Hyun Sohn, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Joo Hyun Sohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ankara University School of Medicine</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Necati Örmeci, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Necati Örmeci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>China</country>
    <country>Indonesia</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.</citation>
    <PMID>26047908</PMID>
  </reference>
  <reference>
    <citation>Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310-335. doi: 10.1002/hep.28906. Epub 2016 Dec 1. Erratum in: Hepatology. 2017 Jul;66(1):304.</citation>
    <PMID>27786365</PMID>
  </reference>
  <reference>
    <citation>Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009 Oct;6(10):573-82. doi: 10.1038/nrgastro.2009.149. Epub 2009 Sep 1. Review.</citation>
    <PMID>19724251</PMID>
  </reference>
  <reference>
    <citation>Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):708-719. doi: 10.1016/S2468-1253(18)30232-2. Review.</citation>
    <PMID>30215362</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 6, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hepatopancreatobiliary Surgery Institute of Gansu Province</investigator_affiliation>
    <investigator_full_name>Xiaolong Qi</investigator_full_name>
    <investigator_title>Director, Institute of Portal Hypertension</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

